Efficacy and safety of topical hirudin (Hirudex): a double-blind, placebo-controlled study
Stamenova PK, Marchetti T, Simeonov I (2001) · European Review for Medical and Pharmacological Sciences · n=60
Perfil del estudio
- Diseño
- single-center, double-blind, placebo-controlled randomized clinical trial of a topical hirudin-containing cream (Hirudex; Hirudo medicinalis extract 280 UI/100g) for acute musculoskeletal bruises (Bulgaria)
- Tamaño de la muestra (n)
- 60
- Intervención
- Hirudex cream containing Hirudo medicinalis extract 280 UI/100g, applied 3-4 times daily for 5 days (15-20 total administrations) (n=30)
- Comparador
- Matching placebo cream applied with identical dosing regimen for 5 days (n=30); double-blinded for both patients and investigators
- Punto final primario
- Improvement in three major efficacy parameters (bruise size, pain, hematoma resolution) at each follow-up visit; overall efficacy assessment by patient and investigator at end of study
- Resultado primario
- Highly statistically and clinically significant improvement in Hirudin group across all three major efficacy parameters at each follow-up visit (p<0.001 vs placebo); both patient-rated and investigator-rated overall efficacy significantly better in Hirudin arm at end of study
- Duración del seguimiento
- 5 days of treatment plus end-of-study assessment
- PMID
- 11863317
Hallazgos clave
- Only published PubMed-indexed double-blind placebo-controlled RCT of a topical leech-derived (Hirudo medicinalis extract) product in PubMed
- Statistically significant benefit for all three efficacy parameters at each follow-up visit (p<0.001)
- Tests a topical cream formulation - distinct from whole-leech therapy - containing 280 UI hirudin per 100g cream
- Bulgarian registration study supporting Hirudex cream for mild-to-moderate bruises with or without hematoma
- Important boundary case for the registry: distinguishes leech-derived pharmaceutical from whole-leech device application
Limitaciones
- Small sample (n=60) limits subgroup analyses
- Single-center Bulgarian trial - generalizability untested in broader populations
- Tests acute bruise/hematoma indication only, not chronic venous insufficiency or other leech-therapy targets
- Cream formulation only - does not generalize to other hirudin delivery routes (injectable lepirudin, etc.)
- Short 5-day treatment period; no long-term follow-up data
Implicaciones clínicas
Stamenova 2001 is important as the only double-blind placebo-controlled RCT in the PubMed-indexed hirudo-related literature, testing a topical hirudin cream formulation for acute bruises. It does not support whole-leech therapy efficacy but does provide proof-of-concept evidence that topical hirudin extract can produce clinical benefit in superficial soft-tissue injury. For clinicians, the trial is a useful reference point when distinguishing whole-leech device application (FDA K040187) from leech-derived pharmaceutical products. The cream is not currently marketed in the US, but the underlying biochemistry (hirudin as a thrombin inhibitor) supports the general mechanistic case for topical anticoagulant formulations in superficial vascular conditions.
Estudios relacionados
Effect of taleeq (leech therapy) in dawali (varicose veins)
Nigar Z, Alam MA (2011)
Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial
Fuchs J, Cannon CP (1995)
Medicinal leech therapy in venous congestion and various ulcer forms: Perspectives of Western, Persian and Indian medicine
Koeppen D, Aurich M, Pasalar M, Rampp T (2020)